JAK2 and acute lymphoblastic leukemia: We first evaluated the effects of JAK2 and mTOR inhibitors in two JAK2-driven human Ph-like B-ALL cell lines: MHH-CALL-4, which harbors IGH-CRLF2 translocation and the JAK2 I682F mutation, and MUTZ-5 with IGH-CRLF2 translocation and the JAK2 R683G mutation.